Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval ...

Vertex said all 12 achieved levels of blood glucose in the range recommended by the American Diabetes Association (ADA). Type 1 diabetes treatment requires blood glucose monitoring and frequent or ...

Vertex also remains active in diabetes cell therapy, including in partnership with CRISPR. In March, Vertex paid $100 million for non-exclusive rights to its partner’s CRISPR-Cas9 technology in ...

VX-264 and zimislecel came from Vertex’s 2019 acquisition of privately held Semma Therapeutics. The $950 million deal established Vertex’s presence in type 1 diabetes therapy R&D.

Zimislecel, Vertex’s islet cell therapy, remains on track for Phase 3 completion in 2025, with regulatory submissions expected in 2026. The market’s back, and these 3 income stocks are thriving.

FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study By Reuters November 1, 20233:29 AM PDTUpdated November 1, 2023 ...